Genix Pharmaceuticals Corporation
GENX.V
TSX
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -96.55% | -80.95% | -64.20% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -96.55% | -80.95% | -64.20% |
| Cost of Revenue | -- | -- | 10,215.38% | 10,238.46% | 2,119.67% |
| Gross Profit | -- | -- | -7,982.35% | -4,703.45% | -7,450.00% |
| SG&A Expenses | -33.41% | -33.41% | -33.61% | -24.60% | -30.53% |
| Depreciation & Amortization | -25.00% | 0.00% | -99.21% | -99.60% | -99.74% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -67.85% | -66.72% | -8.77% | -29.73% | -46.66% |
| Operating Income | 67.48% | 66.33% | 7.78% | 29.10% | 46.38% |
| Income Before Tax | -134.88% | -341.70% | 97.96% | 98.03% | 97.24% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -134.88% | -341.70% | 97.96% | 98.03% | 97.24% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -134.88% | -341.70% | 97.96% | 98.03% | 97.24% |
| EBIT | 67.48% | 66.33% | 7.78% | 29.10% | 46.38% |
| EBITDA | 73.70% | 66.53% | -46.80% | -62.95% | -43.62% |
| EPS Basic | -120.00% | -344.44% | 97.99% | 98.03% | 97.15% |
| Normalized Basic EPS | 56.52% | 44.19% | -2.38% | 12.24% | 23.33% |
| EPS Diluted | -120.00% | -344.44% | 97.99% | 98.03% | 97.15% |
| Normalized Diluted EPS | 56.52% | 44.19% | -2.38% | 12.24% | 23.33% |
| Average Basic Shares Outstanding | 1.38% | 0.54% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 1.38% | 0.54% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |